About 1 in 8 Americans have used GLP-1s for weight loss — but more than three-quarters quit taking them within two years.
An early clinical trial suggests a minimally invasive procedure called duodenal mucosal resurfacing may reduce weight regain after people stop drugs such as semaglutide or tirzepatide. Patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results